ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1008

Immune Responses to Infection and Autoimmune Diseases in the UK Biobank

Choa Yun1, May A. Beydoun2, Lenore Launer2 and Minkyo Song3, 1National Institute on Aging, Rockville, MD, 2National Institute on Aging, Baltimore, MD, 3National Institutes on Aging, Baltimore, MD

Meeting: ACR Convergence 2024

Keywords: autoimmune diseases, Epidemiology, Infection

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Epidemiology & Public Health Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Infections have been implicated as potential triggers for autoimmune responses, but studies primarily focused on the history of infection linked with autoimmune diseases. Large-scale longitudinal studies on antibodies to infections and their associations with autoimmune diseases are limited. By exploring associations between seropositivity to infection and prevalent and incident autoimmune diseases, we aim to better understand the etiologic role of infection in autoimmune diseases.

Methods: We analyzed data on serum samples from 9,429 randomly selected UK Biobank participants who have been tested for 45 antibody responses to 20 pathogens (human herpes [HHV], hepatitis, polyoma, papilloma [HPV] and retroviruses, as well as Chlamydia trachomatis, Helicobacter pylori, Toxoplasma gondii) using a bead-based multiplex platform. The association between seropositivity and autoimmune diseases was assessed with multivariable odds ratios (ORs) and 95% confidence intervals (CIs) using logistic regression for prevalent and multivariable hazard ratios (HRs) and 95% CIs using Cox regression for incident cases. Forty-eight autoimmune diseases were ascertained using ICD codes and self-reported diagnosis. Multiple testing was adjusted using Bonferroni correction.

Results: 517 (5.5%) had at least one autoimmune disease at baseline (59% women). Among individuals with autoimmune diseases, BKV showed the highest seropositivity (96.5%) and HIV-1 the lowest (0%). Seropositivity to JCV was associated with any prevalent autoimmune disease in both sexes (OR [95% CI] 1.40 [1.08-1.80]); antibodies to hepatitis B virus (HBV) with Graves’ disease (GD) in men (17.99 [3.93-82.00]) and HHV-7 with polymyalgia rheumatica (PR) in women (0.14 [0.04-0.43]). Among nominal significance (p< 0.05), OR ranged from 0.22 (HHV-7/ PR) to 6.42 (HBV/GD) in both sexes; 0.13 (HHV-6/ankylosing spondylitis [AS]) to 10.18 (HTLV-1/AS) in men; 0.18 (HHV-7/rheumatism) to 29.96 (HBV/AS) in women. Of 8,912 autoimmune disease-free individuals, 679 developed new autoimmune diseases (median follow-up 7.5 years). Baseline seropositivity to herpes simplex virus-1 (HSV-1) was inversely associated with aplastic anemia (AA) (HR 0.10 [95% CI 0.02-0.32]). HRs for nominal association ranged from 0.18 (BKV/sarcoidosis) to 12.37 (HCV/ulcerative colitis (UC)) in both sexes; 0.07 (HSV-1/pernicious anemia) to 23.07 (HCV/UC) in men, 0.08 (HHV-7/vasculitis) to 149.07 (HIV-1/primary sclerosing cholangitis) in women.

Conclusion: Our study provides a comprehensive investigation of antibodies to infectious agents and autoimmune diseases in a population cohort. Inverse associations indicate that infections may modulate the immune system and suppress pro-inflammatory processes or could reflect an altered immune status of the host. Conversely, positive associations suggest that infections could trigger autoimmunity through mechanisms like molecular mimicry. By elucidating these pathogen associations, our research significantly advances our understanding of autoimmune disease etiology and provides insights for targeted interventions to reduce infection-related autoimmune risks.

Supporting image 1

Figure 1. Significant associations between seropositivity to infection and prevalent (top)/incident (bottom) autoimmune disease in men and women combined
The numbers represent odds ratios (top)/hazard ratios (bottom)
*Significant at Bonferroni cut-off (p<0.002272727)
HSV1: Herpes Simplex virus_1, HSV2: Herpes Simplex virus_2, VZV: Varicella Zoster Virus, EBV: Epstein-Barr Virus, CMV: Human Cytomegalovirus, HHV6: Human Herpesvirus-6, HHV6A: Human Herpesvirus-6A, HHV6B: Human Herpesvirus-6B, HHV7: Human Herpesvirus-7, HBV: Hepatitis B Virus, HCV: Hepatitis C Virus, BKV: Human Polyomavirus BKV, JCV: Human Polyomavirus JCV, MCV: Merkel Cell Polyomavirus MCV, HPV16: Human Papillomavirus type_16, HPV18: Human Papillomavirus type_18, HIV1: Human Immunodeficiency Virus, C. trachomatis: Chlamydia trachomatis, H. pylori: Helicobacter pylori, T. gondii: Toxoplasma gondii

Supporting image 2

Figure 2. Significant associations between seropositivity to infection and prevalent autoimmune disease by sex
The numbers represent odds ratios
*Significant at Bonferroni cut-off (p<0.002272727)
HSV1: Herpes Simplex virus_1, VZV: Varicella Zoster Virus, EBV: Epstein-Barr Virus, HHV6: Human Herpesvirus-6, HHV6A: Human Herpesvirus-6A, HHV6B: Human Herpesvirus-6B, HHV7: Human Herpesvirus-7, KSHV: Kaposi’s Sarcoma-Associated Herpesvirus, HBV: Hepatitis B Virus, HCV: Hepatitis C Virus, BKV: Human Polyomavirus, HTLV1: Human T-Lymphotropic Virus_1, BKV: Human Polyomavirus BKV, JCV: Human Polyomavirus JCV, HPV16: Human Papillomavirus type_16, HPV18: Human Papillomavirus type_18, HIV1: Human Immunodeficiency Virus, C. trachomatis: Chlamydia trachomatis, H. pylori: Helicobacter pylori

Supporting image 3

Figure 3. Significant associations between seropositivity to infection and incident autoimmune disease by sex
The numbers represent hazard ratios
HSV1: Herpes Simplex virus_1, VZV: Varicella Zoster Virus, EBV: Epstein-Barr Virus, HHV6: Human Herpesvirus-6, HHV6A: Human Herpesvirus-6A, HHV6B: Human Herpesvirus-6B, HHV7: Human Herpesvirus-7, KSHV: Kaposi’s Sarcoma-Associated Herpesvirus, HBV: Hepatitis B Virus, HCV: Hepatitis C Virus, HTLV1: Human T-Lymphotropic Virus_1, HIV1: Human Immunodeficiency Virus, BKV: Human Polyomavirus, JCV: Human Polyomavirus JCV, MCV: Merkel Cell Polyomavirus MCV, HPV16: Human Papillomavirus type_16, HPV18: Human Papillomavirus type_18, C. trachomatis: Chlamydia trachomatis, H. pylori: Helicobacter pylori


Disclosures: C. Yun: None; M. Beydoun: None; L. Launer: None; M. Song: None.

To cite this abstract in AMA style:

Yun C, Beydoun M, Launer L, Song M. Immune Responses to Infection and Autoimmune Diseases in the UK Biobank [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/immune-responses-to-infection-and-autoimmune-diseases-in-the-uk-biobank/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/immune-responses-to-infection-and-autoimmune-diseases-in-the-uk-biobank/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology